綠康生化(002868.SZ):證監會終止審查公司公開發行可轉債申請
格隆匯3月3日丨綠康生化(002868.SZ)公佈,公司於2021年1月22日召開第三屆董事會第二十三次(臨時)會議及第三屆監事會第二十一次(臨時)會議,審議並通過了《關於終止公司公開發行可轉換公司債券事項並撤回申請文件的議案》,2021年2月19日,公司召開2021年第一次臨時股東大會,審議並通過了上述議案,並向中國證監會提交《關於撤回公開發行可轉換公司債券申請文件的請示》,主動撤回公開發行可轉換公司債券的申報材料。
2021年3月2日,公司收到中國證監會出具的《中國證監會行政許可申請終止審查通知書》(【2021】24號),中國證監會根據《中國證券監督管理委員會行政許可實施程序規定》第二十條的有關規定,決定終止對該行政許可申請的審查。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.